Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
Lawrence CoreyPeter B GilbertMichal JuraskaDavid C MontefioriLynn MorrisShelly T KarunaSrilatha EdupugantiNyaradzo M MgodiAllan C deCampErika RudnickiYunda HuangPedro GonzalesRobinson CabelloCatherine OrrellJavier R LamaFatima LaherErica M LazarusJorge SanchezIan FrankJuan HinojosaMagdalena E SobieszczykKyle E MarshallPamela G MukwekwerereJoseph MakhemaLindsey R BadenJames I MullinsCarolyn WilliamsonJohn HuralM Juliana McElrathCarter BentleySimbarashe TakuvaMargarita M Gomez LorenzoDavid N BurnsNicole EspyApril K RandhawaNidhi KocharEstelle Piwowar-ManningDeborah J DonnellNirupama SistaPhilip AndrewJames G KublinGlenda E GrayJulie E LedgerwoodJohn R MascolaMyron S Cohennull nullPublished in: The New England journal of medicine (2021)
VRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates provided proof-of-concept that bnAb prophylaxis can be effective. (Supported by the National Institute of Allergy and Infectious Diseases; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 ClinicalTrials.gov numbers, NCT02716675 and NCT02568215.).